We are live on ! Find out more
SABSW icon

SAB Biotherapeutics Warrant
SABSW

6 hedge funds and large institutions have $21.1K invested in SAB Biotherapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more capital invested

Capital invested by funds: $8.34K → $21.1K (+$12.7K)

14% less funds holding

Funds holding: 7 → 6 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
3
Closed
2
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
+$18.6K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$69
2
NA
NewEdge Advisors
Louisiana
-$33
3
Bank of America
Bank of America
North Carolina
-$3
4
CS
Clear Street
New York
-$3
5
GS
GTS Securities
Florida
-$3

SABSW Hedge Fund Activity: Q1 2026 in Review

6 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2026, worth a combined $21.1K — up 152% from $8.34K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SABSW and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.

The largest buyer was LMR Partners, opening a new position worth an estimated $18.6K. The largest seller was UBS Group, cutting an estimated $69.

  • 6 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2026, down from 7 in Q4 2025.
  • Funds reported $21.1K of SAB Biotherapeutics Warrant stock for Q1 2026, up 152% quarter-over-quarter.
  • 1 fund opened new SAB Biotherapeutics Warrant positions in Q1 2026 and 2 closed out, a net change of -1 holder.
  • The largest SAB Biotherapeutics Warrant buyer in Q1 2026 was LMR Partners, an estimated $18.6K added.
  • The largest SAB Biotherapeutics Warrant seller in Q1 2026 was UBS Group, an estimated $69 sold.

Based on aggregated 13F filings for Q1 2026.